Valeo Financial Advisors LLC Trims Stock Holdings in Stryker Co. (NYSE:SYK)

Valeo Financial Advisors LLC trimmed its holdings in Stryker Co. (NYSE:SYK) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,102 shares of the medical technology company’s stock after selling 182 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Stryker were worth $2,927,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Stryker by 43.6% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 15,475 shares of the medical technology company’s stock worth $5,601,000 after buying an additional 4,696 shares during the period. Nvest Financial LLC raised its holdings in shares of Stryker by 126.3% in the third quarter. Nvest Financial LLC now owns 1,577 shares of the medical technology company’s stock worth $570,000 after buying an additional 880 shares during the period. Fermata Advisors LLC increased its holdings in Stryker by 10.4% during the 3rd quarter. Fermata Advisors LLC now owns 1,427 shares of the medical technology company’s stock worth $515,000 after purchasing an additional 134 shares during the period. West Coast Financial LLC increased its holdings in Stryker by 0.4% during the 3rd quarter. West Coast Financial LLC now owns 33,554 shares of the medical technology company’s stock worth $12,122,000 after purchasing an additional 133 shares during the period. Finally, Independence Bank of Kentucky increased its holdings in Stryker by 40.4% during the 3rd quarter. Independence Bank of Kentucky now owns 4,264 shares of the medical technology company’s stock worth $1,540,000 after purchasing an additional 1,228 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 220,068 shares of company stock worth $71,811,372 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Up 0.6 %

Shares of Stryker stock opened at $355.60 on Friday. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $374.63. The stock has a market cap of $135.47 billion, a P/E ratio of 40.59, a P/E/G ratio of 2.73 and a beta of 0.91. The stock’s 50 day simple moving average is $351.84 and its 200-day simple moving average is $343.05. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The firm had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same period in the prior year, the firm posted $2.54 earnings per share. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. Analysts predict that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Monday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.53%.

Wall Street Analyst Weigh In

Several research firms have commented on SYK. Needham & Company LLC raised their price objective on Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. BTIG Research raised their price objective on Stryker from $360.00 to $374.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. Barclays increased their target price on Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Finally, Stifel Nicolaus dropped their target price on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $379.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.